03-16-2018 08:42 AM CET - Health & Medicine
Print

Autism-Pipeline Review H1 2018

Press release from: ReportsWeb
Reportsweb
Reportsweb


Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review, H1 2018, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

Publisher's Pharmaceutical and Healthcare latest pipeline guide Autism-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 6, 3, 1, 25, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Complete report is available@ www.reportsweb.com/inquiry&RW00011444203/sample

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
-The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Company Profile

4D Pharma PLC
Addex Therapeutics Ltd
AgeneBio Inc
Anima Biotech Ltd
APeT Holding BV
Bantam Pharmaceutical LLC
BioHealthonomics Inc
BrainStorm Cell Therapeutics Inc
Confluence Pharmaceuticals LLC
Coronis NeuroSciences Ltd
Curemark LLC
DRI Biosciences Corp
Evgen Pharma Plc
GW Pharmaceuticals Plc
Heptares Therapeutics Ltd
Immuron Ltd
Intra-Cellular Therapies Inc
Leading BioSciences Inc
MedDay SA
Omeros Corp
OptiNose US Inc
Otsuka Holdings Co Ltd
Ovensa Inc
RespireRx Pharmaceuticals Inc
SkySea Pharmaceutical Inc
Sumitomo Dainippon Pharma Co Ltd

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries

Pune:
505, 6th floor, Amanora Township,
Amanora Chambers, East Block,
Kharadi Road, Hadapsar, Pune-411028

This release was published on openPR.
News-ID: 981256 • Views: 575
More releasesMore releases

You can edit or delete your press release here: